These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15274044)

  • 1. Variants of the orexin2/hcrt2 receptor gene identified in patients with excessive daytime sleepiness and patients with Tourette's syndrome comorbidity.
    Thompson MD; Comings DE; Abu-Ghazalah R; Jereseh Y; Lin L; Wade J; Sakurai T; Tokita S; Yoshida T; Tanaka H; Yanagisawa M; Burnham WM; Moldofsky H
    Am J Med Genet B Neuropsychiatr Genet; 2004 Aug; 129B(1):69-75. PubMed ID: 15274044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines.
    Hungs M; Fan J; Lin L; Lin X; Maki RA; Mignot E
    Genome Res; 2001 Apr; 11(4):531-9. PubMed ID: 11282968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
    Nishino S; Kanbayashi T
    Sleep Med Rev; 2005 Aug; 9(4):269-310. PubMed ID: 16006155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A variant in orexin receptor-2 is associated with self-reported daytime sleepiness in the Japanese population.
    Miyagawa T; Shimada M; Honda Y; Kodama T; Tokunaga K; Honda M
    J Hum Genet; 2022 Jun; 67(6):377-380. PubMed ID: 35034961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of amylase release by Orexin is mediated by Orexin 2 receptor in AR42J cells.
    Harris DM; Go VL; Reeve JR; Wu SV
    Pancreas; 2002 Nov; 25(4):405-10. PubMed ID: 12409837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights.
    Ritchie C; Okuro M; Kanbayashi T; Nishino S
    Curr Neurol Neurosci Rep; 2010 May; 10(3):180-9. PubMed ID: 20425033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypocretin/Orexin Receptor Pharmacology and Sleep Phases.
    Sun Y; Tisdale RK; Kilduff TS
    Front Neurol Neurosci; 2021; 45():22-37. PubMed ID: 34052813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic organization of mouse orexin receptors: characterization of two novel tissue-specific splice variants.
    Chen J; Randeva HS
    Mol Endocrinol; 2004 Nov; 18(11):2790-804. PubMed ID: 15256537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
    Hoyer D; Jacobson LH
    Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hypocretin/orexin system in health and disease.
    Nishino S
    Biol Psychiatry; 2003 Jul; 54(2):87-95. PubMed ID: 12873797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The present and future of synthetic orexin receptor agonists.
    Saitoh T; Sakurai T
    Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sleep, feeding, and neuropeptides: roles of orexins and orexin receptors.
    Mieda M; Yanagisawa M
    Curr Opin Neurobiol; 2002 Jun; 12(3):339-45. PubMed ID: 12049942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins.
    Zhu Y; Miwa Y; Yamanaka A; Yada T; Shibahara M; Abe Y; Sakurai T; Goto K
    J Pharmacol Sci; 2003 Jul; 92(3):259-66. PubMed ID: 12890892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orexins/hypocretins: pain regulation and cellular actions.
    Chiou LC; Lee HJ; Ho YC; Chen SP; Liao YY; Ma CH; Fan PC; Fuh JL; Wang SJ
    Curr Pharm Des; 2010; 16(28):3089-100. PubMed ID: 20687883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors.
    Smart D; Jerman JC; Brough SJ; Neville WA; Jewitt F; Porter RA
    Br J Pharmacol; 2000 Apr; 129(7):1289-91. PubMed ID: 10742282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hypocretin neurotransmission system in myotonic dystrophy type 1.
    Ciafaloni E; Mignot E; Sansone V; Hilbert JE; Lin L; Lin X; Liu LC; Pigeon WR; Perlis ML; Thornton CA
    Neurology; 2008 Jan; 70(3):226-30. PubMed ID: 18195268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes.
    Willie JT; Chemelli RM; Sinton CM; Tokita S; Williams SC; Kisanuki YY; Marcus JN; Lee C; Elmquist JK; Kohlmeier KA; Leonard CS; Richardson JA; Hammer RE; Yanagisawa M
    Neuron; 2003 Jun; 38(5):715-30. PubMed ID: 12797957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness.
    Martínez-Rodríguez JE; Lin L; Iranzo A; Genis D; Martí MJ; Santamaria J; Mignot E
    Sleep; 2003 May; 26(3):287-90. PubMed ID: 12749547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy.
    Mishima K; Fujiki N; Yoshida Y; Sakurai T; Honda M; Mignot E; Nishino S
    Sleep; 2008 Aug; 31(8):1119-26. PubMed ID: 18714784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postnatal development of orexin/hypocretin in rats.
    Yamamoto Y; Ueta Y; Hara Y; Serino R; Nomura M; Shibuya I; Shirahata A; Yamashita H
    Brain Res Mol Brain Res; 2000 May; 78(1-2):108-19. PubMed ID: 10891590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.